Enterprise Value
6.446B
Cash
15.56B
Avg Qtr Burn
N/A
Short % of Float
3.01%
Insider Ownership
65.11%
Institutional Own.
17.59%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMIRNATY (BNT162b2) Details COVID-19, Infectious disease | Approved Quarterly sales | |
BNT316 (ONC-392) Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Data readout | |
Combined modified mRNA vaccine (Influenza A/B + COVID-19) Details Infectious disease, COVID-19, Influenza | Phase 3 Initiation | |
Autogene cevumeran (BNT122) (w/ with atezolizumab and chemotherapy) Details Solid tumor/s, Pancreatic cancer, Cancer | Phase 2 Data readout | |
BNT113 Details Head and neck cancer, Human papillomavirus | Phase 2 Data readout | |
Autogene cevumeran (BNT122) (RO7198457) Details Solid tumor/s, Colorectal cancer | Phase 2 Data readout | |
BNT116 +/- cemiplimab Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
Phase 2 Data readout | ||
Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details Solid tumor/s, Non-small cell lung carcinoma, Bladder cancer, Melanoma | Phase 2 Interim update | |
BNT325 (DB-1305) Details Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s | Phase 1/2 Data readout | |
BNT323 (DB-1311) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
BNT167 Details Vaccine, Shingles | Phase 1/2 Update | |
BNT211 Details Solid tumor/s, Cancer | Phase 1/2 Initiation | |
BNT164 Details Vaccine, Tuberculosis | Phase 1 Data readout | |
BNT116 +/- cemiplimab Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Update | |
BNT221 Details Melanoma | Phase 1 Update |